Icon: enlarge
Moderna headquarters in Cambridge (Massachusetts): Partnership should continue
Photo: JOSEPH PREZIOSO / AFP
According to a newspaper report, the British-Swedish pharmaceutical company AstraZeneca has sold its stake in the US biotech company Moderna.
AstraZeneca sold its 7.7 percent package for more than a billion dollars after shares in the US pharmaceutical company soared because of the breakthrough in the coronavirus vaccine, The Times reported on Sunday.
It is not clear over what period of time the UK-based pharmaceutical company extended the sale of its stake.
One can only guess at the motives.
Obviously, the high price level of the Moderna share, which invited you to take profits.
Experts are convinced that the opportunity could be unique because, despite the current hope in the fight against Covid-19, they do not believe that the mRNA vaccine will be suitable for the masses on a global scale.
It is too expensive and too complicated to use for that.
Despite its finesse, the technology is therefore likely to be tailored for the limited market of more affluent countries for the foreseeable future.
The partnership between the two biotechnology companies would continue for other treatments, the report said.
Moderna, whose emergency vaccine is approved in the US, expects sales of $ 18.4 billion in 2021 as a result of the vaccine.
Neither AstraZeneca nor Moderna initially responded to requests for comment.
Icon: The mirror
mik / Reuters
